Company
eGenesis
Restoring life after organ failure.
Also known as eGenesis, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- eGenesis, Inc.
- egenesisbio.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
eGenesis is a biotechnology company committed to using its multiplex gene editing and genome engineering platform to revolutionize the treatment of organ failure.
Funding snapshot
- Total raised
- $265MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $25.4M2024-02-13
Funding rounds
- Round, 2024
- $25.4M2024-02-13, SEC form D sold, 11 investors
- Round, 2021
- $125M2021-02-26, SEC form D sold, 43 investors
- Round, 2019
- $100M2019-11-01, SEC form D sold, 20 investors
- Round, 2017
- $12.6M2017-03-13, SEC form D sold, 12 investors
- Round, 2016
- $2M2016-08-08, SEC form D sold, 2 investors
Products
- Other
- EGEN-2784
Loading relationship preview